SAN DIEGO - La Jolla Pharmaceutical Company (NASDAQ: LJPC), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases announced that it has signed an option agreement with Leland Stanford Junior University (“Stanford”) that will add proprietary technology to the Company’s programs.
“We look forward to working with Stanford to develop their technology,” said George Tidmarsh, President and CEO of La Jolla. “As we continue to expand our product portfolio, we remain committed to helping patients who suffer from severe diseases for which no treatment is available.”
The option agreement with Stanford allows La Jolla to test the technology potentially adding important and diversified product opportunities to La Jolla’s pipeline. La Jolla is currently testing novel oral formulations using the technology in an animal model of Non-alcoholic Steatohepatitis (NASH). If successful, these product candidates will add to the company’s growing pipeline that includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.